These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11339510)

  • 1. Increased pineal Fdopa uptake is related to severity of Parkinson's disease--a PET study.
    Ghaemi M; Rudolf J; Hilker R; Herholz K; Heiss WD
    J Pineal Res; 2001 May; 30(4):213-9. PubMed ID: 11339510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative assessment of 6-[
    Becker G; Bahri MA; Michel A; Hustadt F; Garraux G; Luxen A; Lemaire C; Plenevaux A
    J Neurochem; 2017 May; 141(4):626-635. PubMed ID: 28294334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive- and motor-related regions in Parkinson's disease: FDOPA and FDG PET studies.
    Nagano-Saito A; Kato T; Arahata Y; Washimi Y; Nakamura A; Abe Y; Yamada T; Iwai K; Hatano K; Kawasumi Y; Kachi T; Dagher A; Ito K
    Neuroimage; 2004 Jun; 22(2):553-61. PubMed ID: 15193583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Performance of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT Imaging in Patients With Parkinson's Disease, Parkinson-Plus Syndrome, and Essential Tremor.
    Sood A; Shukla J; Shree R; Vatsa R; Modi M; Mittal BR
    Clin Nucl Med; 2021 Feb; 46(2):95-102. PubMed ID: 33234920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
    Li CT; Palotti M; Holden JE; Oh J; Okonkwo O; Christian BT; Bendlin BB; Buyan-Dent L; Harding SJ; Stone CK; DeJesus OT; Nickles RJ; Gallagher CL
    Synapse; 2014 Aug; 68(8):325-31. PubMed ID: 24710997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
    Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
    J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
    Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [¹⁸F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [¹⁸F]FDOPA and [¹¹C]DASB PET study in Parkinson's disease.
    Pavese N; Simpson BS; Metta V; Ramlackhansingh A; Chaudhuri KR; Brooks DJ
    Neuroimage; 2012 Jan; 59(2):1080-4. PubMed ID: 21963917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
    Huang WS; Chiang YH; Lin JC; Chou YH; Cheng CY; Liu RS
    J Nucl Med; 2003 Jul; 44(7):999-1005. PubMed ID: 12843212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
    Dhawan V; Ishikawa T; Patlak C; Chaly T; Robeson W; Belakhlef A; Margouleff C; Mandel F; Eidelberg D
    J Nucl Med; 1996 Feb; 37(2):209-16. PubMed ID: 8667046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease.
    Brück A; Aalto S; Nurmi E; Bergman J; Rinne JO
    Neurobiol Aging; 2005 Jun; 26(6):891-8. PubMed ID: 15718048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
    Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
    Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
    Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
    J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.
    Ruottinen HM; Niinivirta M; Bergman J; Oikonen V; Solin O; Eskola O; Eronen E; Sonninen P; Rinne UK
    Synapse; 2001 Apr; 40(1):19-26. PubMed ID: 11170218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
    Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
    Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach.
    Dhawan V; Ma Y; Pillai V; Spetsieris P; Chaly T; Belakhlef A; Margouleff C; Eidelberg D
    J Nucl Med; 2002 Oct; 43(10):1324-30. PubMed ID: 12368370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic anatomy of Parkinson's disease: complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies.
    Eidelberg D; Moeller JR; Dhawan V; Sidtis JJ; Ginos JZ; Strother SC; Cedarbaum J; Greene P; Fahn S; Rottenberg DA
    Mov Disord; 1990; 5(3):203-13. PubMed ID: 2117706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.
    Kaasinen V; Maguire RP; Hundemer HP; Leenders KL
    J Neurol; 2006 Mar; 253(3):340-8. PubMed ID: 16222426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.
    Gallagher CL; Oakes TR; Johnson SC; Chung MK; Holden JE; Bendlin BB; McLaren DG; Xu G; Nickles RJ; Pyzalski R; DeJesus O; Brown WD
    Mov Disord; 2011 Mar; 26(4):614-20. PubMed ID: 21449008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.